Daniels Karen K.

VP of Operations

Adamis Pharmaceuticals Corporation

US, San Diego [HQ]

CIK 1530197

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

149,242

Price per Share :

$0.78

Equivalence :

$116,408.76

Transaction History

S

Form 4

149,242 Shares After Transaction

Value : $61,189.22

Sold $2,186.53

Transaction Date : 11/18/20
- Footnotes
- Form 4
Footnotes:
#1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

#2 The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.

#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4025 to $0.408, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

#4 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.
M

Form 5

149,242 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 02/21/20
- Footnotes
- Form 5
Footnotes:
#1 Represents the vesting of a portion of previously granted restricted stock units (RSU), with shares of common stock to be issued following vesting of the RSUs as described in the award agreement relating to the RSUs.

#2 Includes common stock, as well as restricted stock units granted on January 30, 2019, to the reporting person and previously reported on a Form 4.
S

Form 4

140,664 Shares After Transaction

Value : $122,377.68

Sold $4,767.60

Transaction Date : 08/18/20
- Footnotes
- Form 4
Footnotes:
#1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

#2 The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.

#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.956, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

#4 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.